FibroGen (FGEN) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to a loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.22%. A quarter ago, it was expected that this biotech drug developer would post earnings of $0.75 per share when it actually produced a loss of $4, delivering a surprise of -633.33%.Over the last four quarters, the company has ...

FibroGen (FGEN) Q2 2025 Earnings Call August 11, 2025 05:00 PM ET Speaker0Thank you for standing by and welcome to the FibroGen Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Star one one again. As a reminder, today's program is being recorded.And now I'd like to introduce your host for today's program, Gaye Sheamus from LifeSci Advisors. Please go ahead.Speak ...

FibroGen Reports Second Quarter 2025 Financial Results August 11, 2025 Forward-Looking Statements This presentation contains contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward- looking statements include, but are not limited to, statements regarding the efficacy, safety, convenience, and potential clinical or commercia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdiction of ...

Exhibit 99.1 FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update SAN FRANCISCO, August 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments. "In the second quarter, we continued to make steadfast progress in advancing our clinical pipeline. Trial initiation activities for the Phase 2 monotherapy trial of FG-3246 are progressing, and we expect to start ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant ...

Group 1 - FibroGen, Inc. will announce its second quarter 2025 financial results on August 11 after market close [1] - A conference call and webcast presentation will be held on the same day at 5:00 PM Eastern Time to discuss financial results and provide a business update [2] - The company is focused on developing novel therapies for cancer biology and anemia, with its drug Roxadustat approved in multiple countries for treating anemia in chronic kidney disease patients [3] Group 2 - FibroGen is also evaluating a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. [3] - The company is developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer [3] - FG-3180, an associated CD46-targeted PET biomarker, is also in development [4]

Core Viewpoint - FibroGen, Inc. will implement a 1-for-25 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 p.m. Eastern Time on June 16, 2025, with trading on a split-adjusted basis starting June 17, 2025 [1]. - The number of issued and outstanding shares will decrease from approximately 101.1 million to about 4.0 million shares [3]. - Stockholders will receive cash payments for any fractional shares instead of receiving fractional shares [3]. Group 2: Approval and Purpose - The reverse stock split was approved by stockholders at the 2025 Annual Meeting held on June 4, 2025 [2]. - The primary goal of the reverse stock split is to increase the market price of FibroGen's common stock to meet Nasdaq's minimum bid price requirement [2]. Group 3: Company Overview - FibroGen is a biopharmaceutical company focused on developing novel therapies for cancer and anemia [5]. - Roxadustat is approved in multiple regions for treating anemia in chronic kidney disease patients [5]. - The company is also developing FG-3246, an antibody-drug conjugate for metastatic castration-resistant prostate cancer [5].

Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [4] - The company has an approved product, Roxadustat (爱瑞卓®, EVRENZO™), for treating anemia in chronic kidney disease (CKD) patients in multiple regions including China, Europe, and Japan [4] - FibroGen is evaluating a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. [4] - The company is also developing FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer [4] Leadership Appointment - Dr. Michael Kauffman has been appointed to the Board of Directors of FibroGen effective June 4, 2025 [1] - Dr. Kauffman is recognized as a biotech industry veteran with extensive experience in drug development, particularly in oncology [2] - His expertise is expected to be invaluable as FibroGen progresses its pipeline and approaches near-term clinical milestones [2] Dr. Michael Kauffman's Background - Dr. Kauffman has approximately 30 years of experience in the life sciences industry, focusing on oncology therapeutic products [3] - He currently serves as CEO and president of Nereid Therapeutics Inc. and is a board member of several other biotech companies [3] - His previous roles include co-founder and CEO of Karyopharm, CMO of Onyx Pharma, and leadership positions at Millennium Pharmaceuticals and Biogen [3] - Dr. Kauffman holds an MD and PhD from Johns Hopkins Medical School and is board certified in Internal Medicine [3]

FibroGen Reports First Quarter 2025 Financial Results May 12, 2025 Forward-Looking Statements This presentation contains contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward- looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Fibr ...